Page 14 - Biological E News Today

Biological E partners with Canadian firm to manufacture mRNA vaccines in India Biological E partners with Canadian firm to manufacture mRNA vaccines in India 02 June 2021 | News With a minimum production capacity of 600 million doses in 2022 and a target capacity of 1 billion doses Image credit- shutterstock.com Canadian firm Providence Therapeutics Holdings Inc. and Hyderabad-based Biological E have announced the execution of a term sheet, that sets forth the material terms for a defi...

We curate for you all the Covid-19-related developments and stories of the day worth reading

Biological E -- Indias next Serum, Bharat Biotech of COVID-19 vaccine The acquisition of Akorn India helped Biological E create a potential overall manufacturing capacity of over 1 billion doses per annum. PB Jayakumar | June 2, 2021 | Updated 23:07 IST Providence will provide necessary technology transfer for Biological E to manufacture mRNA vaccines in India. The oldest Indian private vaccine maker, Hyderabad-based Biological E Limited, is emerging as a domestic powerhouse of COVID-19 vaccin...

India News: Biopharma player Biological E has joined hands with Canadian player Providence Therapeutics Holdings Inc for licencing the latter’s mRNA vaccine PTX-C

Read more about Biological E ties up with Canadian firm Providence for mRNA Covid vaccine on Business Standard. The vaccine, named PTX-COVID19-B, is under development in Canada; the deal assumes significance as this gives India access to the mRNA tech

Representative Image Biological E ties up with Canadas Providence to produce mRNA COVID-19 vaccine, to run trials in India and seek EUA ANI | Updated: Jun 01, 2021 19:18 IST Hyderabad (Telangana) [India], June 1 (ANI): Biological E. Limited has tied up with Canadas Providence Therapeutics to locally manufacture its mRNA coronavirus disease (COVID-19) vaccine, the Hyderabad-based company announced on Tuesday, adding it will run a pivotal trial in India, and ...

Biological E. will run a clinical trial of Providences vaccine in India and seek emergency use approval for it, the company said in a statement

Providence will sell up to 30 million doses of its mRNA vaccine to Biological E. (Representational) Hyderabad-based Biological E said on Tuesday it has entered into a licensing agreement with Providence Therapeutics Holdings to manufacture the Canadian companys mRNA COVID-19 vaccine in India. Biological E., which also has a separate deal to produce about 600 million doses of Johnson & Johnsons COVID-19 shot annually, will run a clinical trial of Providences vaccine in India and seek emergency u...

The 2-billion Vaccine Question: How realistic are estimates and whats the current status? SECTIONS Share Synopsis ​The Centre’s plan for 2 billion doses of Covid-19 vaccines by year-end depends on a massive ramp-up of production as well as flawless trials, approval and manufacturing of five new vaccines. How realistic are the estimates? In what stages are the new vaccines now? AP Amid a shortage of Covid-19 vaccines, which has seen many states suspend inoculation sessions, the Centre on May...

Biological E to produce J&Js COVID-19 vaccine alongside its own candidate The infrastructure and plants are completely separate for both the products and we will be producing both independent of each other, Biological Es managing director Mahima Datla said Reuters | May 19, 2021 | Updated 11:42 IST Indias Biological E. will produce the Johnson & Johnson COVID-19 vaccine alongside its own candidate, its managing director told Reuters on Tuesday, which could boost the countrys overall supplies a...